The European Investment Bank (EIB) has announced today that it has provided a €50 million loan facility to MinervaX ApS, a privately held Danish biotechnology company developing a novel, protein-based vaccine against Group B Streptococcus (GBS).
The European Investment Bank (EIB) as the long-term lending institution of the European Union, and GomSpace, an innovative Danish space company, has announced a venture debt financing agreement of up to EUR 18 million. The EIB is a key financier of new space technologies in the European Union, including recent combined EUR 45 million financings into “new space” leaders such as Spire Global, D-Orbit and EnduroSat. Now, the EIB is again supporting space “deep tech” with a venture loan to GomSpace, a Danish space company and pioneer in the global market for nano-satellites, platforms, systems, and space missions. The project concerns research and development for an enlarged platform, including streamlined subsystems for their entire product range. For payloads, the focus is on high frequency applications, which are crucial for the telecom sector.
The European Investment Bank, EIB, is a main player in financing innovation for the European Union. The project will help people in need of hearing aids across the world to get access to technology and care that can improve lives. At the same time, it creates a competitive advantage for the European Union in the hearing healthcare sector. By financing this project, the Bank supports a leading European medical technology company specialised in hearing aids and other acoustic devices to continue to improve the lives of people with hearing loss. The new, modern, high tech hearing aid applications that will be developed as a result of the project will improve the social inclusion possibilities of people living with hearing loss, reduce the risk of cognitive decline and enhance people’s ability to participate in life.